The Heparin-Mobilisable Pool of Platelet Factor 4: A Comparison of Intravenous and Subcutaneous Heparin and Kabi Heparin Fragment 2165

Summary

Some clinical advantages are claimed for low molecular weight heparin so the mobilisation of platelet factor 4 (PF 4) from the endothelial pool by the heparins may be relevant. Unfractionated (UF) heparin has been compared with Kabi heparin fragment 2165. A single intravenous (i. v.) injection of 60 iu/kg heparin was compared with 5000 anti-Xa units of Kabi-2165. Less PF 4 was mobilised by Kabi-2165 and some apparently remained in the pool and was released when the pool was subsequently challenged by giving i.v. heparin. Subcutaneous (s. c.) injections of 5000 iu heparin twice daily were compared with 5000 anti-Xa units of Kabi-2165 once daily, each given for a week. The plasma PF 4 was never raised yet when finally challenged with i.v. heparin the pool was “empty” or refractory after the s.c. heparin but some PF 4 remained after the s.c. Kabi-2165. The two glycosaminogly-cans (GAGs) had widely differing half-lives but the t/2 of the PF 4 mobilised by the two GAGs was similar even though the PF 4 is apparently bound to the GAG.

Keywords

Heparin - Kabi-2165 - Plasma PF4 - Heparin-mobilisable pool of PF4

• References

• 1 O’Brien JR, Etherington MD, Pashley M. Intra-platelet platelet factor 4 (IP · PF 4) and the heparin-mobilisable pool of PF 4 in health and atherosclerosis. Thromb Haemostas 1984; 51: 354-347
• 2 Dawes J, Pumphrey CW, McLaren KM, Prowse CEV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 1982; 27: 65-76
• 3 Celia G, Colby SI, Taylor AD, McCracken L, Parisi AF, Sasahara AA. Platelet factor 4 (PF 4) and heparin-released platelet factor 4 (HR-PF 4) in patients with cardiovascular disorders. Thromb Res 1983; 29: 499-509
• 4 Rao AK, Niewiarowski S, Pranee J, Holt JEC, Harris M, Elfenbein B, Bastl C. Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood 1983; 61: 1208-1214
• 5 Holmer E, Mathson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
• 6 Bergqvist D, Hedner U, Sjörin E, Holmer E. Anti-coagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-391
• 7 Austen DE G, Rhymes IL. A Laboratory Manual of Blood Coagulation. Blackwell’s Scientific Publications; 1975
• 8 Cella G, Scattolo N, Luzzatto G, Girolami A. Effects of low molecular weight heparin on platelets as compared with commercial heparin. Res Exp Med 1984; 184: 227-229
• 9 Ten Cate H, Henny ChP, Mooy MC, ten Cate JW, Surachno JS, Wilmink JM. The anticoagulant and anti-thrombotic effects of a novel heparinoid in haemodialysis patients and in healthy volunteers. Thromb Haemostas 1983; 50: 302 (Abstr)
• 10 O’Brien JR, Etherington MD. 1983. (Unpublished observations)
• 11 Negus D, Friedgood A, Cox SJ, Peel AL G, Wells BW. Ultra-low dose intravenous heparin in the prevention of postoperative deep vein thrombosis. Lancet 1980; 1: 891-894
• 12 Barbar AJ, Kaser-Glanzmann R, Jakabova M, Luscher EF. Characterization of a chondroitin 4-sulphate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochim Biophys Acta 1972; 286: 312-329
• 13 Dawes J, Smith RC, Pepper DS. The release distribution and clearance of human β-thromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-861
• 14 Stern D, Naworth P, Marcum J, Handley D, Kisiel W, Rosenberg R, Stern K. Interaction of antithrombin III with bovine aortic segments. J Clin Invest 1985; 75: 272-279
• 15 Marcum JEA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters bound to the endothelium. J Clin Invest 1984; 74: 341-350
• 16 Thomas DP. Heparin, low molecular weight heparin and heparin analogues. Brit J Haematol 1984; 58: 385-390